Human platelets that were preincubated with porcine elastase aggregated spontaneously upon the addition of fibrinogen. Maximal aggregation to fibrinogen was observed with platelets pretreated with an elastase concentration of 111 tg/ml, and halfmaximal aggregation occurred after treatment with 11 ,ug/ml elastase. Binding of radiolabeled fibrinogen to elastase-treated platelets was specific, saturable, and showed a single class of 48,400±9,697 fibrinogen-binding sites per platelet with a dissociation constant of 6.30±1.48 X i0-M. ATP, apyrase, and the stimulators of platelet adenylate cyclase forskolin, prostaglandin El, prostacyclin, and N6, 2'-O-dibutyryl cyclic AMP did not inhibit the fibrinogen-induced aggregation of elastase-treated platelets. EDTA completely blocked the initiation of aggregation and reversed the fibrinogen-induced aggregation of elastasetreated platelets. Monoclonal and polyclonal antibodies directed against glycoproteins (GP) Ilb and II1a completely blocked the fibrinogen-induced aggregation of elastase-treated platelets. Immunoprecipitates with these antibodies obtained from detergent extracts of surface-radiolabeled, intact, and elastase-treated platelets contained the glycoproteins IUb and IIIa. We conclude that surface proteolysis by low concentrations of elastase can expose fibrinogen-binding sites associated with GPIIb and GPIIIa on the platelet surface, resulting in spontaneous aggregation upon the addition of fibrinogen. These findings may be relevant to hemostatic changes observed in patients with increased levels of circulating elastase.
Introduction
Platelets stimulated by ADP (1) (2) (3) (4) , thrombin (5, 6) , epinephrine (2, 7), or prostaglandin endoperoxides (8, 9) expose receptors specific for fibrinogen. These fibrinogen-binding sites were shown to be associated with glycoproteins (GP)' Ilb and IlIa of the platelet membrane (10) (11) (12) (13) (14) . It is the exposure of these sites on adjoining platelets that results in fibrinogen binding and platelet aggregation. Several laboratories have demonstrated that fibrinogen-binding sites become permanently exposed on the platelet surface as a result ofthe pretreatment ofplatelets with proteolytic enzymes (15) (16) (17) . Platelets pretreated with chymotrypsin or pronase specifically bind fibrinogen and aggregate spontaneously A preliminary report ofthese findings was presented at the 57th Scientific Sessions of the American Heart Association, November 1984, Miami Beach, FL and was published in abstract form, 1984 . Circulation.
70:98.
Please address reprint requests to Dr. Elizabeth Kornecki, Ph.D. Received for publication 17 May 1985 and in revised form 12 November 1985. upon the addition of fibrinogen even in the absence ofADP (or any other platelet agonist). Such proteolytic treatment results in platelets in which fibrinogen binding and the fibrinogen-induced aggregation are no longer sensitive to raised intracellular levels of cyclic AMP (18) . A role for proteases in the modulation of hemostasis and thrombosis has been suggested. Proteases released from human neutrophil granules have been shown to hydrolyze factors involved in blood coagulation and fibrinolysis (19) (20) (21) (22) . Activation of platelets by chymotrypsin-like activity has also been demonstrated (15) (16) (17) 20) . The present study describes the activation of human platelets by extracellular elastase. We demonstrate that low concentrations of elastase (1-10 ,ug/ml) expose specific fibrinogen-binding sites on the platelet surface. The exposure of these receptor sites produces platelets that aggregate spontaneously upon the addition of fibrinogen. These in vitro findings provide experimental support for early studies (23) (27) of the method of Salomon et al. (28) . Reaction products were centrifuged at 2,500 g for 20 min, the supernatants were applied onto cation exchange columns (AG50W-X8; Bio-Rad Laboratories, Richmond, CA), and the 3H precursor nucleotides were eluted with water. After eluting the contents into alumina columns, the [3H]cyclic AMP was eluted with 0.1 M imidazole, pH 7.4. Aliquots of the alumina eluates and 3H nucleotide precursor fractions were counted with a 5-ml scintillation cocktail.
Monoclonal and polyclonal antibodies. Two types of antibodies that were previously shown to inhibit fibrinogen-induced aggregation ofintact, chymotrypsin-and pronase-treated platelets were used. The preparation and characterization of a polyclonal rabbit anti-human, intact platelet membrane antibody and a monoclonal antibody (MA 123) have been described previously ( 17, 29).
'251-Iodination of platelets. Iodogen (1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril; Pierce Chemical Co., Rockford, IL) was used to iodinate the membrane surface of intact and elastase-treated platelets (17).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was performed in 5% stacking gels and in 8.5% separation polyacrylamide slab gels. Molecular weight determinations were made by comparison with reduced samples of a2-macroglobulin (170,000), phosphorylase b (97,400), glutamate dehydrogenase (55,400), and lactate dehydrogenase (36, 500 
Results
The effects of pretreatment with elastase on the aggregation of human platelets is shown in Fig. 1 . Platelets pretreated with Exposure ofFibrinogen Receptors by Surface Proteolysisdependent on the concentration of elastase used during the preincubation period. Fig. 3 . shows that maximal aggregation occurred after treatment with an elastase concentration of 10 U/ 109 platelets/ml (-111 g/ml). Half-maximal aggregation to fibrinogen occurred with platelets treated with an elastase concentration of 1 U/ml (11 tg/ml). A further increase in the concentration of elastase (25 U/ml) resulted in platelets that exhibited decreased ability to aggregate upon the addition of fibrinogen. The response of platelets to a maximal concentration of ADP (10 ,M) was not lost after elastase treatment, as shown by the ability of elastase-treated platelets to undergo a shape change upon the addition of 10 MM ADP (Fig. 3) The fibrinogen-induced aggregation of elastase-treated platelets was dependent on the presence of divalent cations, as evidenced by the finding that EDTA completely inhibited the aggregation of elastase-treated platelets induced by fibrinogen ( Fig. 4 and Table I ). EDTA also reversed the aggregation, as shown in Fig. 4 . The effects of various agents on the fibrinogeninduced aggregation of elastase-treated platelets are shown in Table I . ATP and apyrase had no inhibitory effects, further indicating that the aggregation was not caused by released ADP. Stimulators of platelet adenylate cyclase, agents that completely block the aggregation of ADP-stimulated intact platelets, did not have any effect on the fibrinogen-induced aggregation of elastase-treated platelets. The lack of inhibition of fibrinogeninduced aggregation of elastase-treated platelets by these agents could be due to the proteolysis of prostaglandin receptors on Figure 3 . Effect of increasing concentrations of elastase on ADP-induced shape change and fibrinogen-induced platelet aggregation. Platelets were pretreated with various concentrations of elastase, washed, and resuspended at a concentration of 4 X 108/ml. Aliquots (0.45 ml) were added to cuvettes and stirred at 370C. Fibrinogen (200 Mg/ml) (25 Ml) was added to initiate platelet aggregation. Maximal fibrinogeninduced aggregation (measured as the initial velocity) occurred at an elastase concentration of 12.5 U/ml. This value was then set at 100%.
Platelet shape change (A) was initiated by adding ADP (25 Ml) (10 ,uM, final concentration) to platelet suspensions (0.45 ml) incubated at 370C for 1 min with 5 mM EGTA, pH 7.4. The initial velocity and extent of shape change were measured in both intact (untreated) and elastase-treated platelets exposed to 10 MM ADP. These values obtained with elastase-treated platelets were compared with those obtained with intact (control) platelets. They are expressed as the percent of control. Each value is the average of triplicate samples. Similar results were obtained using five blood donors. the platelet surface, or due to degradation ofthe adenylate cyclase complex by elastase treatment. To test these possibilities, we measured the adenylate cyclase activity of both intact and elastase-treated platelets. We found that treatment of platelets with elastase had no effect on the ability of forskolin or prostacyclin to increase intracellular levels of cyclic AMP (Fig. 5) . We also measured the ability of ADP or epinephrine to inhibit the stimulation of adenylate cyclase in elastase-treated platelets. Fig. 5 demonstrates that the inhibition ofadenylate cyclase activity by ADP and epinephrine in elastase-treated platelets was identical to that of intact (untreated) platelets. The binding of fibrinogen to elastase-treated platelets is shown in Fig. 6 . The specific binding of radiolabeled fibrinogen 4 40,000 1.0 X 10-7 5 52,000 7.4 X 10-7 * Platelets, pretreated with 12.5 U/ 109 platelets per ml of elastase for 1 h at 370C, were washed and resuspended at a concentration of 109 platelets/ml. Radiolabeled fibrinogen (25 Ml) at concentrations ranging from 1 to 1,000 ug/ml, were added to 0.40 ml of the platelet suspension, followed by a 10-min incubation at 220C. 300-;i aliquots were applied over 50 ul of silicon oil, centrifuged, and the radioactivities in the pellets were counted. To examine the surface proteins, we radiolabeled intact and elastase-treated platelets with 1251 and analyzed the protein pattern by SDS-PAGE followed by autoradiography. The main protein components that were iodinated on the surface of intact platelets were GPIIb (Mr 120,00) and GPIIIa (Mr 100,000) as shown previously (17). No significant differences were observed in the labeling of these proteins in elastase-treated, compared with untreated, intact platelets (Fig. 7) . The detergent solubilized extracts of surface-labeled intact and elastase-treated platelets NR R Figure 7 . Surface-radiolabeled, _ _ t _ intact, and elastase-treated Fig. 8 , lane 2 (for intact platelets) and lane 4 (for elastase-treated platelets). GPIIb and GPIIIa were immunoprecipitated from intact and elastase-treated platelet extracts. Also, a 200,000-mol-wt protein co-precipitated with the GPIIb/GPIIIa complex of intact and elastase-treated platelets. Fig. 9 shows that both polyclonal antiplatelet membrane antibody and monoclonal antibody 123 could completely inhibit the fibrinogen-induced aggregation of elastase-treated platelets.
Discussion
The objective of this investigation was to determine whether treatment of platelets with the proteolytic enzyme elastase has significant effects on platelet function. The data presented here demonstrate that low concentrations of elastase (1.0-10 ,g/ml)
can cause an irreversible exposure of fibrinogen-binding sites on the platelet surface, producing platelets that can be aggregated directly by fibrinogen. The binding of radiolabeled fibrinogen to elastase-treated platelets was specific and saturable with the number of fibrinogen-binding sites ranging from 24,000 to 84,000 per platelet (mean±SEM was calculated to be 41,000±13,645). The dissociation constant for fibrinogen ranged treated platelets was dependent on the concentration of fibrinogen, and on the concentration of elastase used during the preincubation period. The maximal level of aggregation that could be attained with fibrinogen was achieved using concentrations of elastase of 10-12 U/109 ml platelets (11 ,ug/ ml). Incubation with 1 U ofelastase (11 g/ml) produced a halfmaximal response ofthese platelets to fibrinogen. The fibrinogeninduced aggregation of elastase-treated platelets was dependent also on the presence of divalent cations. EDTA completely inhibited the aggregation of elastase-treated platelets. At maximal aggregation, the addition of EDTA completely reversed the aggregation. In contrast to intact (untreated) platelets, addition of ADP was not necessary to induce aggregation ofelastase-treated platelets. However, ADP was able to induce a maximal shape change in elastase-treated platelets that was similar to that observed in intact platelets. Neither the extent nor the initial velocity of this shape change was altered by pretreatment of platelets with up to 500 ,g (45 U) of elastase. Also, the affinity for ADP was not altered, since the 50% effective dose for ADP for inducing shape change in elastase-treated platelets (0.37±0.09 ,uM) did not differ significantly from that of intact platelets (0.26±0.03 pM). These values are very similar to those reported previously for ADP-induced shape change of intact platelets by other investigators (30) (31) (32) . We conclude that under certain conditions, fibrinogen-induced aggregation of human platelets can be independent of shape change. This conclusion is consistent with previous reports by Peerschke and Zucker (33) and Wheeler et al. (34) using cytochalasins, and our studies of chymotrypsintreated platelets (4, (16) (17) (18) .
The fibrinogen-induced aggregation of elastase-treated platelets was not inhibited by forskolin or prostacyclin, agents that completely inhibited the ADP-induced, fibrinogen-dependent aggregation of intact platelets. tase-treated platelets. We found that elastase-treated platelets responded to forskolin and prostacyclin, and increased cyclic AMP levels to the same extent as did intact platelets. In addition, we found that the inhibition of the adenylate cyclase system of elastase-treated platelets by ADP and epinephrine was identical to that of intact (untreated) platelets. The treatment of platelets with either 125 or 500 ,g of elastase had no effect on the ability of ADP or epinephrine to inhibit the prostacycin or forskolininduced stimulation ofthe platelet adenylate cyclase. This finding indicates that the prostaglandin receptor, the ADP and epinephrine receptors, as well as the mechanism that couples these receptors to adenylate cyclase, remain functionally unchanged after treatment ofthe platelet surface with elastase. These findings also indicate that the adenylate cyclase system becomes dissociated from aggregation after surface proteolysis.
To investigate the possible mechanism(s) whereby elastase treatment causes exposure of fibrinogen-binding sites, we used monoclonal and polyclonal antibodies characterized in previous studies (17, 29). We found that monoclonal antibody 123 and a polyclonal antiplatelet membrane antibody inhibited the fibrinogen-induced aggregation of elastase-treated platelets. In addition, we observed that monoclonal antibody 123 and polyclonal antimembrane antibody immunoprecipitated the membrane glycoproteins GPIIb and GPIIIa from detergent-solubilized, surface-radiolabeled, elastase-treated platelets. This would indicate that sites formed by the association of the GPIIb/GPHIa complex or sites found on GPIIb or GPIIIa molecules appear to be involved in the binding of fibrinogen to the surface of elastase-treated platelets. In previous studies (17) we have found that treatment of platelets with high concentrations of chymotrypsin (500-1,000 ,g/ml) resulted in the appearance of a 66,000-Mr protein derived from GPIIIa on the platelet surface. The formation of such a derivative was not detected on the surface ofelastase-treated platelets. Due to differences in the specificities of the enzymes, it is possible that elastase produces only small fragments from GPIIb or GPIIIa molecules, smaller than those produced by chymotrypsin or pronase-treatment. These changes may be sufficient to expose fibrinogen-binding sites on the platelet surface without necessarily forming a 66,000-mol-wt fragment from GPIIIa. Alternatively, it is possible that elastase exposes fibrinogen-binding sites without producing changes in the GPIIb/ IlIa complex itself, but by hydrolyzing other surface proteins that mask the fibrinogen-binding sites in intact, resting platelets.
The results of the present study could have important clinical implications. The effects of pancreatic proteases on platelet function have been implicated in the development of systemic complications in pancreatitis (35) . Proteolysis of platelet surface glycoproteins, in vivo, has been associated with cirrhosis of the liver (36) . After the studies reported here were completed, Brower et al. (37) have reported that platelets treated with human neutrophil elastase lose the ability to aggregate in response to thrombin and ristocetin. However, spontaneous aggregation to added fibrinogen was not tested by Brower et al. (37) . In recent studies (38) , we found that human platelets pretreated with low concentrations of elastase purified from human granulocytes can be aggregated directly by fibrinogen. Egbring et al. (19) previously reported that the plasma of patients with septicemia or acute leukemia contain high levels of granulocyte elastase, and this was associated with thrombocytopenia. Although plasma antiproteinases (a,-antitrypsin and a2-macroglobulin) form complexes with elastase, significant proteolytic activity was still detectable in the plasma of these patients even in the presence of the antiproteases (19). Furthermore, the proteases in such complexes are still active, since they appear to have the ability to proteolyze specific substrates (39-42). Our in vitro data suggest, therefore, that under certain pathophysiological conditions circulating elastase could cause irreversible platelet activation in vivo. The clinical implications of our findings must be carefully investigated, since the process described here may play a role in hemostatic changes observed in patients with septicemia, acute leukemia, pancreatitis (19, 35) , and possibly other diseases with increased circulating elastase.
